GAMMA Investing’s Atea Pharmaceuticals AVIR Stock Holding History

GAMMA Investing’s Portfolio AVIR Stock Details AVIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.55K	Buy	490 +399	+438%	+$2.04K	﹤0.01%	3879
2026 Q2	$423	Sell	91 -18	-17%	-$90	﹤0.01%	4010
2026 Q1	$586	Buy	+109	New	+$501	﹤0.01%	3923

Other funds holding AVIR

VCM

Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's AVIR Position: Q3 2026 in Review

GAMMA Investing increased its Atea Pharmaceuticals (AVIR) stake by 438% in Q3 2026, buying an estimated $2.04K and bringing the position to 490 shares worth $2.55K. The position accounts for ﹤0.01% of the portfolio, ranked #3879.

GAMMA Investing first reported a position in AVIR in Q1 2026 and has held it in 3 quarters since. 3 funds tracked by Wall St. Rank hold AVIR as of Q3 2026.

GAMMA Investing held 490 shares of Atea Pharmaceuticals worth $2.55K as of Q3 2026.
GAMMA Investing bought 399 Atea Pharmaceuticals shares in Q3 2026, an estimated $2.04K.
Atea Pharmaceuticals made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3879 holding.
GAMMA Investing first reported a position in Atea Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
3 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.